Bharat Biotech Applied for Phase III Trial of Booster Dose of Nasal Vaccine

The country's leading biotechnology company Bharat Biotech has applied to the DGCI (Pharmaceutical Controller General of India) for the Phase III trial of a booster dose of its nasal anti-Covid vaccine. Giving this information on Monday, sources said that this booster dose can be given to those people who have got any of the vaccine either Covaxin or Covishield. As we all know these days the country is currently at risk of a new and more infectious Omicron variant of the corona virus. Cases of infection have started increasing once again in the country and it is feared that by February next year, the third wave of corona pandemic may come in the country. Day by day the cases of the variant of the corona virus are increasing that too in different states. Even to counter it the internati...

Read More

Yogi Government Approves Vaccine For Children, One Child Will Take Three Doses

Day by day the corona cases are increasing with a boom in India and abroad. Now when all are facing the threat of increasing Omicron variant of corona these days now the central government and all the state governments are working in order to tackle the increasing cases and to avoid the boom of cases that India may observe if we do not follow the protocols properly. Going with the same strategy of saving the life of people from Covid even to save from getting infected Uttar Pradesh government has launched its campaign. According to sources, soon children and adolescents above 12 years of age will be vaccinated with anti-coronavirus vaccine in Uttar Pradesh. Sick, handicapped children will be vaccinated first on priority basis as they are more prone to get infected. The state government...

Read More

Indian firm Bharat Biotech Will Be Commencing Phase I Trials Of Intranasal Covid-19 Vaccine Candidate Next Month

PTI reported Bharat Biotech chairman and managing director, Krishna Ella, as saying in a session of TiE Global Summit that two more facilities could be established for vaccine manufacturing including Covaxin, a vaccine for the coronavirus. Besides Covaxin, Bharat Biotech has been actively working on developing another vaccine, for which it tied up with Washington University School of Medicine in St Louis for the novel "chimp-adenovirus" (Chimpanzee adenovirus), a single dose intranasal vaccine for Covid-19. “I think it will enter into Phase I (next month) because it is going to be a single-dose vaccine. The clinical trial process is also going to be faster.” In September, Bharat Biotech signed a licensing agreement with Washington University School of Medicine in St. Louis fo...

Read More